Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04532827
Other study ID # 3531101
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date August 18, 2020
Est. completion date September 30, 2023

Study information

Verified date January 2023
Source Finnish Institute of Occupational Health
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Persistent physical symptoms (PPS) might diminish studying or workability and daily functioning without a clear medical or environment-related explanation. Psychosocial, patient-involving treatments that support individuals' abilities managing with the PPS and health behaviours have shown promising effects in treating PPS but the acceptability of these treatments among symptomatic individuals is low. This study aims to assess the effectiveness of an eHealth intervention based on relational frame theory and acceptance and commitment therapy on PPS with two focus groups, among participants with indoor air associated disabling symptoms or persistent, chronic fatigue. This study will compare web program enhanced with video-based individual case formulation with treatment as usual. The web program includes 10 one weeks (pilot included 6 two weeks) modules. In addition to patient-reported outcomes, ecological momentary assessments are conducted to provide real-time data on functioning and national registers are used to obtain information on health-care use and social benefits. Data collection begins in August 2020 and will continue until 2023.


Description:

Background: Frequent physical symptoms are common in the general population with over 90 per cent of the population reporting symptoms at some level. In some cases, they become persistent diminishing workability and daily functioning and associate with increased healthcare usage and sick leaves independently of other somatic or psychiatric comorbidities. Persistent physical symptoms (PPS) challenge health care systems as it is estimated that up to 4-30 per cent of primary health care visits are due to PPS without a clear medical explanation. Psychosocial, patient-involving treatments, such as cognitive-behavioural psychotherapy (CBT), that support individuals' abilities managing with the PPS and health behaviours have shown promising effects in treating PPS but so far, evidence-based treatments have resulted only in small to moderate effect sizes. The acceptability of these treatments among symptomatic individuals is also low - presumably because of the stigma related to the ambiguity of the PPS´ status as a medical condition. A stronger orientation to personalized treatment protocols is needed to improve the treatment efficacy and applicability. This study will assess the effects of an eHealth intervention based on relational frame theory and acceptance and commitment therapy on PPS with two focus groups, among participants with indoor air associated disabling symptoms or persistent, chronic fatigue. Methods: Using a randomized controlled design (RCT) with two parallel groups in a 1:1 ratio, the investigators will compare ACT/RFT-based web program enhanced with individual case formulation with treatment as usual. The web program intervention includes 10 one weeks (pilot included 6 two weeks) modules that each ask to complete the module and included training in two weeks. The web program is in Finnish. Participants will be asked to complete outcome questionnaires at baseline before the interview for inclusion, after the interview (randomization) and at 3, 6- and 12-months' follow-up after the randomization. The intervention group receives also a questionnaire four weeks after the beginning of the web program. In addition, ecological momentary assessments are also conducted to provide real-time data on functioning and national registers are used to obtain information on healthcare use and social benefits to complete patient-reported outcomes. Eligible participants will be randomized to either the intervention or to TAU. The primary outcome will be a health-related quality of life. The secondary outcome measures are symptoms, illness perceptions, psychological flexibility and workability. Further, the investigators will assess whether any effect of the intervention on the primary outcome is mediated by the case formulation. The baseline data collection begins in August 2020 and will continue until 2022, follow-up data collection will continue until 2023.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 105
Est. completion date September 30, 2023
Est. primary completion date July 1, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Fluent Finnish (web-program is in Finnish) - Duration of the symptoms Onset of symptoms with disability maximum of 3 years before the study - Symptomatology A) Indoor air-related symptoms or B) Persistent, chronic fatigue A) Indoor air-related symptoms 1. Self-reported symptoms attributed to indoor (non-industrial) environments include: i) symptoms from at least two different organ systems eg. respiratory, digestive or nervous system. 2. Symptoms recurrently i) occur in more than one indoor environment or ii) continue despite environmental improvements (e.g. study or work arrangements and/or workplace repairs) or B) Chronic fatigue 1. Post-exertional malaise and/ or post-exertional fatigue. 2. Unrefreshing sleep or disturbance of sleep quantity or rhythm disturbance. 3. Multiorgan symptoms i) Pain, often widespread, ii) Two of more neurological or cognitive symptoms, iii) At least two symptoms of following categories: Autonomic manifestations, neuroendocrine manifestations or immune manifestations - Duration and severity of the condition: Symptoms minimum of six months; Symptoms are not lifelong and result in substantial functional restrictions in daily life. Exclusion Criteria: - Work situation: Long sick leave (=3 months) without return to work plan, not actively participating in study or work life (retired or unemployed) - Medical reasons 1. Some serious and/or acute medical disease or illness explains the symptoms i) Somatic disease that explains the symptoms (e.g. uncontrolled asthma, hypothyroidism, sleep apnea) 2. Psychiatric disorder (bipolar disorder, psychotic disorders, alcohol and/or drug dependency or abuse, eating disorders, and/or severe mood disorders) 3. Developmental disorders - Current psychotherapy - Other Patient refusal

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Case formulation with web-program
The first meeting includes an interview to establish understanding on the participant´s symptomatology and current life situation, a case formulation (CF) will be build based on it. The CF is presented in the second session and modifications can be made to ensure acceptability for the participant. Goals for web program (WB) are set based on the CF and understanding of the factors contributing to the participant´s wellbeing. WB modules are instructed to complete during the week. Modules include psychoeducation, experiential exercises and training aimed at improving wellbeing and psychological flexibility. Web-therapist will offer written feedback. The participants can contact the therapist via the WB and al messages will be replied within one week. Automatic reminders will be sent if a participant has not been active in the WB, the therapists will call participants who have discontinued using the WB.

Locations

Country Name City State
Finland Finnish Institute of Occupational Health Helsinki Uusimaa

Sponsors (3)

Lead Sponsor Collaborator
Finnish Institute of Occupational Health the Hospital District of Helsinki and Uusimaa, The Social Insurance Institution of Finland

Country where clinical trial is conducted

Finland, 

Outcome

Type Measure Description Time frame Safety issue
Other Interview of treatment acceptance Interview for sample of intervention participants about the treatment acceptance (qualitative) 12 months randomisation
Other Engagement to the intervention Total number of logins and time during the web-program, modules and exercises completed. 14 weeks after randomisation.
Other Reasons for discontinuing If participant discontinues he / she will be contacted. Through study completion, an average of 1 year
Other The Finnish national health registers The Finnish national health registers to assess health care expenditures: Data on outpatient visits (AvoHILMO data), data on inpatient care (HILMO data), data on occupational health care use, information on prescribed and reimbursed prescription medicines purchases, information on rights for special reimbursement for medicines and information on sickness and disability benefits and rehabilitation with diagnoses At baseline (i.e. at self-referral), at 12 months after randomisation
Primary The 15D questionnaire (health related quality of life) The 15D is a utility-based generic, standardized measure, comprising the following 15 dimensions that describe physical, mental, and social well-being: mobility, vision, hearing, breathing, sleeping, eating, speech, excretion, usual activities, mental function, discomfort and symptoms, depression, distress, vitality, and sexual activity. Each dimension is graded by the respondent on a scale ranging between 1 and 5, where 1 indicates an experience of no problems at all with the dimension and 5 indicates severe problems. Thus, the 15D can be used to measure a vast number of health states. We will use the 15D data both to derive 15D overall scores with values from 1 (full health) to 0 (being dead), and to obtain dimensional symptom profiles. Chance from baseline (i.e. at self-referral) to after randomisation (i.e. after clinical assessment), and to 6 and 14 weeks and to 6 and to 12 months after randomisation
Secondary Demographic questions: age (years) At baseline (i.e. at self-referral)
Secondary Demographic questions: gender (male, female, prefer not to say) At baseline (i.e. at self-referral)
Secondary Demographic questions: marital status (Unmarried, married or cohabiting, divorced or separation, widow) At baseline (i.e. at self-referral)
Secondary Demographic questions: education (basic, secondary, higher) At baseline (i.e. at self-referral)
Secondary Demographic questions: daily exercise One item of the frequency of the exercise on a six point likert scale (No weekly exercise - 4 times/week or more) At baseline (i.e. at self-referral)
Secondary Demographic questions: Diet Two items of the diet on a six point likert scale (have daily regular eating habits - have no regular eating habits; Caffeine consumption never - 7 or more proportion per day) At baseline (i.e. at self-referral)
Secondary Social support and loneliness Five questions of frequency of perceived loneliness and and social support in challenging situations (likert scale). At baseline (i.e. at self-referral), and 12 months after randomisation
Secondary Smoking, Alcohol Use Disorders Identification Test (Audit-C) At baseline (i.e. at self-referral), and 12 months after randomisation
Secondary Questions about health: Self-reported health Five point likert scale (very poor - very good) At baseline (i.e. at self-referral), and 12 months after randomisation
Secondary Questions about health: Self-reported diseases (diagnosed by medical doctor) At baseline (i.e. at self-referral), and 12 months after randomisation
Secondary Questions about health: medication Self-reported medication during past four weeks (name, dose, purpose of use) At baseline (i.e. at self-referral), and 12 months after randomisation
Secondary Questions about health: Health care unit An open question of the participant´s health care provider. At baseline (i.e. at self-referral), and 12 months after randomisation
Secondary Questions about health: Information seeking Questions about health information seeking from different sources (on a six point likert scale) At baseline (i.e. at self-referral), and 12 months after randomisation
Secondary Questions about health: height in meters height in meters to calculate BMI kg/m^2 At baseline (i.e. at self-referral)
Secondary Questions about health: weight in kilograms weight in kilograms to calculate BMI kg/m^2 At baseline (i.e. at self-referral)
Secondary Work characteristics Questions about participant work characteristics (working hours, field of industry etc) At baseline (i.e. at self-referral), and 12 months after randomisation
Secondary Symptoms related to environmental factors Questions whether environmental factors such as mold or water damage in buildings, electromagnetic fields, chemicals or indoor air have associated with symptoms and have they associated with avoidance behavior (yes - no). At baseline (i.e. at self-referral), and 6 and 14 weeks and 6 and 12 months after randomisation
Secondary Health worries and health worries related to environmental factors Questions about health worries in general and related to environmental factors (scale 0 not worried at all - 10 extremely worried) At baseline (i.e. at self-referral), and 14 weeks, and 6 and 12 months after randomisation
Secondary Environmental factors: influence on everyday life Questions about the influence of environmental factors on everyday life (scale 0 no consequences - 10 severe consequences) At baseline (i.e. at self-referral), and 14 weeks, and 6 and 12 months after randomisation
Secondary Resiliency (SOC-3) Time Frame: At baseline (i.e. at self-referral)
Secondary Personality Inventory (PK5) Time Frame: At baseline (i.e. at self-referral)
Secondary Questions about sleep quality, sleeping patterns Length of sleep (weekdays and weekends, hours) At baseline (i.e. at self-referral), and 14 weeks, and, 6 and 12 months after randomisation
Secondary Questions about sleep quality, sleeping patterns Nap (frequency per week and length, hours) At baseline (i.e. at self-referral), and 14 weeks, and 6 and 12 months after randomisation
Secondary Questions about sleep quality, sleeping patterns Self-reported i) sleep quality, ii) night awakening iii) sleep disorders and iv) frequency of sleeping medicine usage at five point likert scale. At baseline (i.e. at self-referral), and 14 weeks, and 6 and 12 months after randomisation
Secondary Questions about sleep quality, sleeping patterns Self-reported quality of rest and rhythmicity at four point likert scale. At baseline (i.e. at self-referral), and 14 weeks, and 6 and 12 months after randomisation
Secondary Fatigue Questionnaire about perceived fatigue and its´consequences on daily functioning during past six months. At baseline (i.e. at self-referral), and 14 weeks, and 6 and 12 months after randomisation
Secondary Generalized Anxiety Disorder 7 (GAD-7) At baseline (i.e. at self-referral), and 14 weeks, and 6 and 12 months after randomisation
Secondary Insomnia Severity Index (ISI) At baseline (i.e. at self-referral), and 14 weeks, and 6 and 12 months after randomisation
Secondary Patient Health Questionnaire-15 (PHQ-15) At baseline (i.e. at self-referral), and 14 weeks, and 6 and 12 months after randomisation
Secondary The Patient Health Questionnaire (PHQ-9) At baseline (i.e. at self-referral), and 14 weeks, and 6 and 12 months after randomisation
Secondary AIDO Healthcare app: daily mood and fatigue 1.5, 3.5 and 12 months after randomisation
Secondary The Acceptance and Action Questionnaire -II AAQ-7 At baseline (i.e. at self-referral), and 6 and 14 weeks and, 6 and 12 months after randomisation
Secondary Comprehensive assessment of Acceptance and Commitment Therapy CompACT At baseline (i.e. at self-referral), and 14 weeks, 6 and 12 months after randomisation
Secondary Cognitive Fusion Questionnaire (CFQ-7) At baseline (i.e. at self-referral), and 6 and 14 weeks and, 6 and 12 months after randomisation
Secondary Whiteley index -7 questionnaire At baseline (i.e. at self-referral), and 14 weeks and 6 and 12 months after randomisation
Secondary White Bear Suppression Inventory (WBSI) At baseline (i.e. at self-referral), after randomization and 14 weeks and, 6 and 12 months after randomisation
Secondary Five Facet Mindfulness Questionnaire (FFMQ) At baseline (i.e. at self-referral), after randomization and 12 months after randomisation
Secondary Toronto alexithymia scale (TAS-20) At baseline (i.e. at self-referral)
Secondary Illness Perception Questionnaire At baseline (i.e. at self-referral) and 6 and 14 weeks and 6 and 12 months after randomisation
Secondary Self-assessed current ability to study or work One question about current ability to study or work on a scale 1-10. At baseline (i.e. at self-referral) and 14 weeks 6 and 12 months after randomisation
Secondary Own prognosis of ability to study or work two years from now One question about of work ability two years from now (scale Unlikely; Not certain; Relatively certain) At baseline (i.e. at self-referral) and 14 weeks 6 and 12 months after randomisation
Secondary Self-assessed stress and recovery One question about stress and recovery on a scale 1-10. At baseline (i.e. at self-referral) and 14 weeks and 6 and 12 months after randomisation
Secondary Daily functioning in three sub-domains. Three questions about daily functioning (work, social life, home) on a scale 1-10 each At baseline (i.e. at self-referral and 14 weeks and 6 and 12 months after randomisation
Secondary Working Alliance Inventory (WAI) - patient version for eHealth intervention after randomization and 6 and 14 weeks after randomisation
Secondary Treatment satisfaction Six items of treatment satisfaction based on Seligman´s report (1995). The effectiveness of psychotherapy: The Consumer Reports study. American psychologist, 50(12), 965. after randomization and 6 and 14 weeks after randomisation
See also
  Status Clinical Trial Phase
Recruiting NCT05454683 - Melatonin and Zinc Administration on Cardinal Symptoms in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome N/A
Completed NCT01686074 - Motor Control in Chronic Fatigue Syndrome and Fibromyalgia N/A
Completed NCT02075489 - Acupressure for Pain Management and Fatigue Relief in Gulf War Veterans N/A
Completed NCT01651754 - Humoral and Cellular Immune Responses After Influenza Vaccination in Patients With Postcancer Fatigue and in Patients With Chronic Fatigue Syndrome N/A
Completed NCT00540254 - Behavioral Insomnia Therapy With Chronic Fatigue Syndrome Phase 1/Phase 2
Active, not recruiting NCT00071162 - Genetics of Fibromyalgia N/A
Withdrawn NCT04870476 - Feasibility and Acceptability of the Internet-delivered Treatment "One Step at the Time" for Bodily Distress Syndrome N/A
Completed NCT05730660 - Quercetin Phytosome® Chronic Fatigue Syndrome N/A
Recruiting NCT04542161 - Assessment of N-Acetylcysteine as Therapy for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Phase 2
Recruiting NCT03807973 - Tracking Peripheral Immune Cell Infiltration of the Brain in Central Inflammatory Disorders Using [Zr-89]Oxinate-4-labeled Leukocytes. Phase 1
Recruiting NCT05719493 - Effectiveness and Health Benefits of a Nutritional, Chronobiological and Physical Exercise Intervention in Fibromyalgia and Chronic Fatigue Syndrome (SYNCHRONIZE +) N/A
Recruiting NCT05967052 - Investigation of Treating Chronic Fatigue Syndrome After COVID With Pharmacotherapy (Pregabalin) or Complex Rehabilitation Phase 2
Terminated NCT01730495 - Tumor Necrosis Factor-alpha Inhibition Using Etanercept in Chronic Fatigue Syndrome Phase 2
Completed NCT01156909 - B-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome Phase 2
Completed NCT01650636 - Patient-Partner Stress Management Effects on Chronic Fatigue Syndrome Symptoms and Neuroimmune Process N/A
Completed NCT01046370 - A Pilot Study of Amygdala Retraining Program in Patients With Chronic Fatigue Syndrome, Chronic Fatigue and Fibromyalgia N/A
Completed NCT00100412 - Hyporeactivity and Gulf War Illness N/A
Recruiting NCT06128967 - A Multicenter, Adaptive, Randomized, doublE-blinded, Placebo-controlled Study in Participants With Long COVID-19: The REVIVE Trial Phase 3
Completed NCT02669212 - Myalgic Encephalomyelitis Chronic Fatigue at the National Institutes of Health N/A
Not yet recruiting NCT06011135 - Exploring Worry in CFS/ME